Recursion licenses TxFM RNA foundation model to Tempus AI for oncology use in USD 12 million deal

• Recursion Pharmaceuticals expanded its data partnership with Tempus AI, extending the term to six years from the effective date.
• Revised annual license fees set at USD 14 million on each of the third, fourth, and fifth anniversaries, with at least USD 4 million paid in cash.
• Removed Recursion’s right to terminate for convenience; reduced the total unique de-identified records it can access over the term.
• Separate two-year oncology license grants Tempus use of Recursion’s TxFM RNA model; Tempus to pay USD 12 million in two installments.
• Tempus to provide access to de-identified pathology records with linked clinical data during the TxFM license term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001601830-26-000112), on September 21, 2026, and is solely responsible for the information contained therein.